Report Overview

The Brazil Antifungal Drugs market size stood at USD xx billion 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Antifungal drugs are commonly used to cure fungal infections due to unclean, unhygienic, and damp environments. Invasion of epithelial tissue by microscopic organisms leads to fungal infections. Systemic fungal infections are caused due to indigestion or inhalation of spores, leading to fungal pneumonia. Although most fungal infections and diseases are commonly non-lethal, they are very uncomfortable to the host, and their common occurrence is responsible for the rising antifungal drugs market. Antifungal drugs work via various mechanisms such as by inhibiting cell wall formation, cell membrane disruption, and cell division.



Market Drivers

The major factors driving the market are rising awareness of fungal infections with the increasing incidence of antifungal infections, rising government and corporate funding in the industry. Further, more and more public-private partnerships in the pharmaceutical industry and the rising popularity of over-the-counter antifungal drugs for dermal infections are vastly responsible for increasing the market size. Also, the increase of population with weak, in whom the occurrence of fungal infections is much more than average, will drive the market.

Major fungal Disease

In terms of indication, the market is segmented into dermatophytosis, aspergillosis, candidiasis, and others. Dermatophytosis is a non-fatal superficial infection on skin. Dermatophytosis is anticipated to dominate the market owing to an increase in prevalence of dermatophytosis cases. The prevalence of dermatophytosis cases is associated with an age group of participants ranging from 11-20 years and 21-30 years.

Candidiasis is the second most dominating segment. Owing to increase in nosocomial infection in the patients being treated in invasive care units for various health problems.